Scholarlink

Background <p>Antimicrobial resistance (AMR) poses a global public health and economic challenge, significantly contributing to poor outcomes of bacteria bloodstream infections (BSI). There is a paucity of local data on outcomes of AMR BSIs in Nigeria. This prospective cohort study determined outcomes and healthcare costs of BSIs stratified by resistance status.</p> Method <p>Data were prospectively collected from enrolled participants (neonates, children and adults) with susceptible (cohort 1) and resistant (cohort 2) BSIs caused by <i>Enterobacterales</i>, <i>Pseudomonas</i> spp, <i>Acinetobacter</i> spp., <i>Staphylococcus aureus</i>, and <i>Enterococcus</i> spp, and a control group without BSI (cohort 3), at the University of Port Harcourt Teaching Hospital between April and November 2025. Outcomes (in-hospital mortality and extra length of hospital stay, LOS) were compared between the three cohorts using time-dependent and multi-state regression models that adjusted for patients’ characteristics, time-varying cofounders and competing risks, while healthcare costs were compared using Students’ <i>t’</i> test and analysis of variance.</p> Results <p>A total of 952 patients were recruited, with 330 neonates, 271 children and 351 adults. The overall prevalence of bacteria-confirmed BSI was 18.1%, with neonatal BSI of 27.3%, childhood BSI of 12.5% and adult BSI of 13.7% (<i>p</i> &lt; 0.0001). In-hospital mortality was higher for healthcare onset (HO) compared to community onset (CO) BSI (<sub>sd</sub>HR:1.7 (0.65–4.5)], MRSA compared to MSSA BSI [<sub>sd</sub>HR: 4.1 (0.49–33.5)], and clindamycin-resistant compared to clindamycin-susceptible <i>S. aureus</i> BSI (<sub>sd</sub>HR: 6.8 (0.36–129.4)]. Multistate modelling showed that HO-BSI caused extra LOS of 2.28 days compared to CO-BSI, resistant BSI caused extra LOS of 1.72 days compared to susceptible BSI, MRSA-BSI caused extra LOS of 2.83 days compared to MSSA-BSI, and ESBL-BSI caused extra LOS of 4.28 days compared to non-ESBL-BSIs. Healthcare costs, catastrophic expenditures and impoverishment from out-of-pocket spending were high for all groups but generally higher for patients with HO and resistant BSIs.</p> Conclusion <p>Compared to susceptible bacterial BSIs, resistant bacterial BSIs are associated with higher mortality, extra length of hospital stays and excess healthcare costs. Policies to reduce the burden of resistant BSIs should focus on improving infection prevention and control and antimicrobial stewardship practices in both hospital settings and the community.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mortality outcomes and economic burden of antimicrobial-resistant bacterial bloodstream infections in a Nigerian tertiary hospital

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Babatunde Akinola,
  • Ifeyinwa Nwafia,
  • Chinemerem Onwuliri,
  • Henry Ekechi,
  • Kabir Abdullahi,
  • John Adedoyin,
  • Calista Osuocha,
  • Winifred Okache,
  • Vivian Bellonwu,
  • Donald Udah,
  • Sunday Malgwi,
  • Ahmed Abdulkarim,
  • Marian Oyebade,
  • Dooshima Kwange,
  • Adetomiwa Gbolade,
  • Ibrahim Dauda,
  • Oluchukwu Gbogboade,
  • Chidindu Mmadu-Okoli,
  • Esther Ayandipo,
  • Agatha Akpaka,
  • Charles Salifu,
  • Mary Alex-Wele,
  • Ugochukwu Nwokoro,
  • Obed John,
  • Dahiru Iliyasu,
  • Samuel Taiwo,
  • Tochi Okwor,
  • Ridwan Yahaya,
  • Dozie Ezechukwu,
  • Jide Idris

摘要

Background

Antimicrobial resistance (AMR) poses a global public health and economic challenge, significantly contributing to poor outcomes of bacteria bloodstream infections (BSI). There is a paucity of local data on outcomes of AMR BSIs in Nigeria. This prospective cohort study determined outcomes and healthcare costs of BSIs stratified by resistance status.

Method

Data were prospectively collected from enrolled participants (neonates, children and adults) with susceptible (cohort 1) and resistant (cohort 2) BSIs caused by Enterobacterales, Pseudomonas spp, Acinetobacter spp., Staphylococcus aureus, and Enterococcus spp, and a control group without BSI (cohort 3), at the University of Port Harcourt Teaching Hospital between April and November 2025. Outcomes (in-hospital mortality and extra length of hospital stay, LOS) were compared between the three cohorts using time-dependent and multi-state regression models that adjusted for patients’ characteristics, time-varying cofounders and competing risks, while healthcare costs were compared using Students’ t’ test and analysis of variance.

Results

A total of 952 patients were recruited, with 330 neonates, 271 children and 351 adults. The overall prevalence of bacteria-confirmed BSI was 18.1%, with neonatal BSI of 27.3%, childhood BSI of 12.5% and adult BSI of 13.7% (p < 0.0001). In-hospital mortality was higher for healthcare onset (HO) compared to community onset (CO) BSI (sdHR:1.7 (0.65–4.5)], MRSA compared to MSSA BSI [sdHR: 4.1 (0.49–33.5)], and clindamycin-resistant compared to clindamycin-susceptible S. aureus BSI (sdHR: 6.8 (0.36–129.4)]. Multistate modelling showed that HO-BSI caused extra LOS of 2.28 days compared to CO-BSI, resistant BSI caused extra LOS of 1.72 days compared to susceptible BSI, MRSA-BSI caused extra LOS of 2.83 days compared to MSSA-BSI, and ESBL-BSI caused extra LOS of 4.28 days compared to non-ESBL-BSIs. Healthcare costs, catastrophic expenditures and impoverishment from out-of-pocket spending were high for all groups but generally higher for patients with HO and resistant BSIs.

Conclusion

Compared to susceptible bacterial BSIs, resistant bacterial BSIs are associated with higher mortality, extra length of hospital stays and excess healthcare costs. Policies to reduce the burden of resistant BSIs should focus on improving infection prevention and control and antimicrobial stewardship practices in both hospital settings and the community.